KNSA Q3'26 Earnings: EPS estimate is 0.37 USD

What happened

Kiniksa Pharmaceuticals will report Q3'26 results on October 27 before the market opens at 7:30 AM ET. Analysts expect revenue of 260.66 million USD and earnings per share of 0.37 USD, according to FactSet estimates.

Confirmed

Global impact / market context

Earnings per share is profit divided by shares outstanding, so the 0.37 USD estimate shows expected profit per share. Revenue is expected at 260.66 million USD, so investors will compare actual results against these targets.

Analyst inference

Kiniksa beat revenue estimates in each of the four prior quarters shown, but missed earnings per share estimates twice earlier in that stretch. That mixed record means the upcoming report will test whether revenue momentum carries through to profit.

Analyst inference

What to watch

1. Watch whether reported Q3'26 revenue reaches the 260.66 million USD estimate or falls short of that analyst target. Confirmed
2. Watch whether reported earnings per share meets the 0.37 USD estimate, since Kiniksa missed this measure in two of the prior quarters shown. Proposed
3. Watch whether revenue growth translates into profit per share, because repeated revenue beats alongside earnings misses would suggest costs are rising faster than sales. Analyst inference

Evidence

• Original source link unavailable